Number of employees
80
Annual revenue
$8700000
Argos Therapeutics, Inc., formerly Merix Bioscience, is a pioneer in immunotherapy. Our focus is bringing to market therapeutic options that not only offer new promise for treatment of intractable diseases, but also an improved safety profile and better patient quality of life during treatment. By combining proprietary knowledge of dendritic cell behavior and enabling presentation of relevant antigens via RNA, Argos’ vaccine therapies unlock the potential of an individual’s own body, retraining the immune system to recognize and target disease at its cellular origin.